HT-100, a COL1A1 inhibitor, was developed for the treatment of Duchenne muscular dystrophy (DMD) by the Akashi Therapeutics pipeline and Collgard Biopharmaceuticals [101–103]. Here, COL1A1 is linked to Duchenne muscular dystrophy.